Effects of Selective Serotonin Reuptake Inhibitors on Endocrine System (Review)

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2024 Jul 29

PMID 39070109

Authors

Carolina Ruiz-Santiago

Carla Valeria Rodriguez-Pinacho

Gilberto Perez-Sanchez

Erika Acosta-Cruz

Affiliations

Soon will be listed here.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are typically prescribed for treating major depressive disorder (MDD) due to their high efficacy. These drugs function by inhibiting the reuptake of serotonin [also termed 5-hydroxytryptamine (5-HT)], which raises the levels of 5-HT in the synaptic cleft, leading to prolonged activation of postsynaptic 5-HT receptors. Despite the therapeutic benefits of SSRIs, this mechanism of action also disturbs the neuroendocrine response. Hypothalamic-pituitary-adrenal (HPA) axis activity is strongly linked to both MDD and the response to antidepressants, owing to the intricate interplay within the serotonergic system, which regulates feeding, water intake, sexual drive, reproduction and circadian rhythms. The aim of the present review was to provide up-to-date evidence for the proposed effects of SSRIs, such as fluoxetine, citalopram, escitalopram, paroxetine, sertraline and fluvoxamine, on the endocrine system. For this purpose, the literature related to the effects of SSRIs on the endocrine system was searched using the PubMed database. According to the available literature, SSRIs may have an adverse effect on glucose metabolism, sexual function and fertility by dysregulating the function of the HPA axis, pancreas and gonads. Therefore, considering that SSRIs are often prescribed for extended periods, it is crucial to monitor the patient closely with particular attention to the function of the endocrine system.

Citing Articles

Reproductive Toxicity Induced by Serotonin-Norepinephrine Reuptake Inhibitors: A Pharmacovigilance Analysis From 2004 to 2023 Based on the FAERS Database.

Xi Y, Bao Z, Guo Q, Wang J, Jing Z, Di J CNS Neurosci Ther. 2024; 30(12):e70176.

PMID: 39670536 PMC: 11638886. DOI: 10.1111/cns.70176.

Vortioxetine as an alternative treatment for somatic symptom disorder: case report.

Furutani N, Nagoshi Y Front Psychiatry. 2024; 15:1496072.

PMID: 39575195 PMC: 11578982. DOI: 10.3389/fpsyt.2024.1496072.

References

Dissanayake W, Sorrenson B, Shepherd P . The role of adherens junction proteins in the regulation of insulin secretion. Biosci Rep. 2018; 38(2). PMC: 5861323. DOI: 10.1042/BSR20170989. View

Lyons D, Ammari R, Hellysaz A, Broberger C . Serotonin and Antidepressant SSRIs Inhibit Rat Neuroendocrine Dopamine Neurons: Parallel Actions in the Lactotrophic Axis. J Neurosci. 2016; 36(28):7392-406. PMC: 6705542. DOI: 10.1523/JNEUROSCI.4061-15.2016. View

Chang H, Chen S, Shen M, Kung M, Chuang L, Chen Y . Selective serotonin reuptake inhibitor, fluoxetine, impairs E-cadherin-mediated cell adhesion and alters calcium homeostasis in pancreatic beta cells. Sci Rep. 2017; 7(1):3515. PMC: 5471211. DOI: 10.1038/s41598-017-03747-0. View

Rowland D, McMahon C, Abdo C, Chen J, Jannini E, Waldinger M . Disorders of orgasm and ejaculation in men. J Sex Med. 2010; 7(4 Pt 2):1668-86. DOI: 10.1111/j.1743-6109.2010.01782.x. View

Pawluski J, Rayen I, Niessen N, Kristensen S, van Donkelaar E, Balthazart J . Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience. 2012; 220:131-41. DOI: 10.1016/j.neuroscience.2012.06.034. View

De Long N, Hyslop J, Raha S, Hardy D, Holloway A . Fluoxetine-induced pancreatic beta cell dysfunction: New insight into the benefits of folic acid in the treatment of depression. J Affect Disord. 2014; 166:6-13. DOI: 10.1016/j.jad.2014.04.063. View

Rinne T, de Kloet E, Wouters L, Goekoop J, De Rijk R, van den Brink W . Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with a history of sustained childhood abuse. Neuropsychopharmacology. 2002; 28(1):126-32. DOI: 10.1038/sj.npp.1300003. View

Berardelli R, Margarito E, Ghiggia F, Picu A, Balbo M, Bonelli L . Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans. J Endocrinol Invest. 2010; 33(9):657-62. DOI: 10.1007/BF03346666. View

Oishi A, Mochizuki Y, Otsu R, Inaba N . Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women. Biopsychosoc Med. 2007; 1:12. PMC: 1899513. DOI: 10.1186/1751-0759-1-12. View

10.

Kotkowska Z, Strzelecki D . Depression and Autoimmune Hypothyroidism-Their Relationship and the Effects of Treating Psychiatric and Thyroid Disorders on Changes in Clinical and Biochemical Parameters Including BDNF and Other Cytokines-A Systematic Review. Pharmaceuticals (Basel). 2022; 15(4). PMC: 9025086. DOI: 10.3390/ph15040391. View

11.

Jackson I . Does thyroid hormone have a role as adjunctive therapy in depression?. Thyroid. 1996; 6(1):63-7. DOI: 10.1089/thy.1996.6.63. View

12.

Koyuncu H, Serefoglu E, Yencilek E, Atalay H, Akbas N, Sarica K . Escitalopram treatment for premature ejaculation has a negative effect on semen parameters. Int J Impot Res. 2011; 23(6):257-61. DOI: 10.1038/ijir.2011.35. View

13.

Wu C, Gong W, Wang Y, Sun J, Zhou H, Zhang Z . Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity. Neurobiol Aging. 2018; 67:137-147. DOI: 10.1016/j.neurobiolaging.2018.03.011. View

14.

Edinoff A, Akuly H, Hanna T, Ochoa C, Patti S, Ghaffar Y . Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021; 13(3):387-401. PMC: 8395812. DOI: 10.3390/neurolint13030038. View

15.

Hage M, Azar S . The Link between Thyroid Function and Depression. J Thyroid Res. 2012; 2012:590648. PMC: 3246784. DOI: 10.1155/2012/590648. View

16.

Grankvist K, Marklund S, Taljedal I . CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem J. 1981; 199(2):393-8. PMC: 1163382. DOI: 10.1042/bj1990393. View

17.

Ulker N, Yardimci A, Kaya Tektemur N, Colakoglu N, Ozcan M, Canpolat S . Chronic exposure to paroxetine or bupropion modulates the pubertal maturation and the reproductive system in female rats. Reprod Biol. 2020; 20(2):154-163. DOI: 10.1016/j.repbio.2020.03.009. View

18.

Jacobsen N, Hansen C, Nellemann C, Styrishave B, Halling-Sorensen B . Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015; 29(7):1729-35. DOI: 10.1016/j.tiv.2015.07.005. View

19.

Gregorian R, Golden K, Bahce A, Goodman C, Kwong W, Khan Z . Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002; 36(10):1577-89. DOI: 10.1345/aph.1A195. View

20.

Hansen C, Larsen L, Sorensen A, Halling-Sorensen B, Styrishave B . The six most widely used selective serotonin reuptake inhibitors decrease androgens and increase estrogens in the H295R cell line. Toxicol In Vitro. 2017; 41:1-11. DOI: 10.1016/j.tiv.2017.02.001. View